Heyy

Hey! How can I help you today?

Make a cheat sheet from these questions since i have no time first give the important ones answers if time permits we'll study remaining Divide them into paper I and 2 btw give answers in text format

Let me read both PDFs first!
Reading File
Running Command

cd /home/daytona/workspace/attachments/733e6aea-b242-4e92-bdea-e62f1ce95eb4/ && python3 -c " import pdfplumber for fname in ['NTRUHS 2K23 MICROBIOLOGY PAPER-1 SUPER-50.pdf', 'NTRUHS 2K23 MICROBIOLOGY PAPER-2 SUPER-50.pdf']: print(f'\n\n========== {fname} ==========') with pdfplumber.open(fname) as pdf: for page in pdf.pages: text = page.extract_text() if text: print(text) "

Got all the questions. Now let me read the medical library skill and generate the cheat sheet. Given budget constraints, I'll use my medical knowledge to produce a high-yield cheat sheet immediately.Here's your complete cheat sheet! I've prioritized the most high-yield topics (marked ⭐) that are most likely to come in exams, with crisp answers you can memorize fast.

NTRUHS 2K23 MICROBIOLOGY - CHEAT SHEET


PAPER 1 - HIGH YIELD ANSWERS


⭐ Q1. HIV/AIDS (Q7)

Structure: Enveloped, ss-RNA retrovirus. Icosahedral core.
  • Structural genes: gag (p24 core), pol (RT, integrase, protease), env (gp120, gp41)
  • Non-structural genes: tat, rev, nef, vif, vpr, vpu
Pathogenesis: HIV binds CD4 + CCR5/CXCR4 -> enters T-helper cell -> RT makes proviral DNA -> integrates -> replication -> CD4 count falls -> AIDS (<200 cells/µL)
Lab Diagnosis:
  • ELISA (screening) -> Western Blot (confirmation)
  • CD4 count, Viral load (PCR)
  • NACO algorithm: 3 rapid tests (A1, A2, A3)
ART: TDF + 3TC + EFV (first line) PEP: Start within 72 hrs, give for 28 days
Opportunistic fungal infections: Candidiasis (most common), Cryptococcal meningitis, PCP (Pneumocystis jirovecii), Histoplasmosis, Aspergillosis

⭐ Q2. Typhoid Fever (Q6)

Agent: Salmonella typhi (Gram -ve rod) Pathogenesis: Feco-oral -> Peyer's patches -> bacteremia -> rose spots, hepatosplenomegaly Widal Test:
  • Positive: O titer ≥1:80, H titer ≥1:160 (single); O ≥1:160 (paired)
  • O = active infection, H = past infection/vaccination
Lab Diagnosis: Gold standard = Blood culture (1st week), Urine/stool culture (3rd week), Bone marrow culture (most sensitive)
Treatment: Ciprofloxacin / Azithromycin / Ceftriaxone Vaccine: Vi polysaccharide (injectable), Ty21a (oral live attenuated) Drug Resistance: MDR typhoid - resistant to Amp, Chloramphenicol, Co-trimoxazole. XDR - also resistant to fluoroquinolones

⭐ Q3. Hypersensitivity Reactions (Q4)

TypeNameMediatorExample
IAnaphylactic/ImmediateIgE, Mast cellsAnaphylaxis, Asthma, Urticaria
IICytotoxicIgG/IgM + ComplementABO incompatibility, Autoimmune hemolytic anemia
IIIImmune ComplexIgG complexes + ComplementSLE, Serum sickness, Post-strep GN
IVDelayed (Cell mediated)T lymphocytesTB (Mantoux), Contact dermatitis, Graft rejection
Shwartzman Reaction: Two injections of endotoxin (preparatory + provocative) -> local (skin) or generalized (DIC, bilateral cortical necrosis)

⭐ Q4. Autoimmunity + SLE (Q1)

Mechanisms of Autoimmunity:
  1. Molecular mimicry (pathogen resembles self Ag)
  2. Polyclonal B cell activation
  3. Sequestered antigen release
  4. Defective Treg function
  5. Bystander activation
SLE: Systemic autoimmune disease
  • ANA (Anti-nuclear antibody) - screening test
  • Anti-dsDNA - specific, correlates with disease activity
  • Anti-Smith (Anti-Sm) - most specific
  • Features: Butterfly rash, arthritis, nephritis, serositis, hematologic changes
  • LE cells seen in peripheral smear
Classification: Organ-specific (Hashimoto's, Type 1 DM, MG) vs Systemic (SLE, RA, Sjogren's)

⭐ Q5. Malaria (Q9)

Plasmodium species: P. falciparum (malignant tertian, most dangerous), P. vivax (benign tertian), P. malariae (quartan), P. ovale
Life Cycle:
  • In mosquito (Anopheles female): Sexual cycle (sporogony) -> Sporozoites
  • In human: Liver (exo-erythrocytic) -> RBC (erythrocytic) -> Trophozoite -> Schizont -> Merozoites
Pathogenesis: Rupture of RBCs -> fever, chills. P. falciparum - cytoadherence, rosetting -> cerebral malaria
Lab Diagnosis:
  • Peripheral smear (Giemsa stain) - Gold standard
  • RDT (Rapid Diagnostic Test) - HRP2 antigen for P. falciparum
  • PCR
Cerebral Malaria: P. falciparum only. Parasitized RBCs block cerebral capillaries. Features: Coma, seizures, mortality ~20%
Treatment: Chloroquine (sensitive), ACT - Artemether+Lumefantrine (falciparum), Primaquine (for P. vivax hypnozoites)
Vaccine: RTS,S (Mosquirix) - first approved malaria vaccine

⭐ Q6. Hepatitis Viruses (Q17)

VirusTypeTransmissionChronicityMarkers
HAVRNAFeco-oralNoAnti-HAV IgM (acute)
HBVDNABlood/sexual/verticalYes (5-10%)HBsAg, HBeAg, Anti-HBc IgM
HCVRNABloodYes (80%)Anti-HCV, PCR
HDVRNA (incomplete)Blood (needs HBV)YesAnti-HDV
HEVRNAFeco-oralNoAnti-HEV IgM
HBV Markers:
  • HBsAg: Surface antigen, first to appear, marker of infection
  • HBeAg: Active replication, high infectivity
  • Anti-HBs: Immunity (natural or vaccine)
  • Anti-HBc IgM: Acute infection
  • Window period: HBsAg gone, Anti-HBs not yet - only Anti-HBc IgM present
Prophylaxis HBV: Vaccine (3 doses: 0, 1, 6 months) + HBIG for post-exposure

⭐ Q7. Sterilization & Disinfection (Q5)

Sterilization: Complete destruction of all microorganisms including spores.
Moist Heat (most reliable):
  • Autoclave: 121°C, 15 psi, 15 min (kills spores)
  • Pasteurization: 62°C/30 min (LTLT) or 72°C/15 sec (HTST)
  • Boiling: 100°C, 20 min (not sterilization - doesn't kill spores)
Dry Heat:
  • Hot air oven: 160°C/60 min, 170°C/30 min, 180°C/10 min
High Level Disinfectants: Glutaraldehyde 2% (Cidex), Hydrogen peroxide 6%, Formaldehyde, Ortho-phthalaldehyde (OPA)
Gaseous Disinfectants: Ethylene oxide (ETO) - heat-sensitive items; Formaldehyde vapor
Chemical Disinfectants: Phenol (carbolic acid, first antiseptic), Alcohol 70%, Chlorine compounds (hypochlorite), Iodine/Povidone-iodine

⭐ Q8. ELISA (Q3)

Principle: Antigen-antibody reaction detected by enzyme-linked antibody producing color change.
Types:
  1. Direct ELISA - detect antigen
  2. Indirect ELISA - detect antibody (most common in serology)
  3. Sandwich ELISA - most sensitive, detect antigen
  4. Competitive ELISA
Uses: HIV screening, HBsAg, Dengue NS1, TORCH screening
Enzymes used: HRP (Horseradish peroxidase), Alkaline phosphatase

⭐ Q9. Dengue (Q8)

Agent: Flavivirus, ss RNA, 4 serotypes (DEN 1-4), transmitted by Aedes aegypti mosquito
Pathogenesis: Dengue fever -> Dengue hemorrhagic fever (DHF) -> Dengue shock syndrome (DSS). Secondary infection with different serotype -> antibody-dependent enhancement (ADE) -> more severe disease
Clinical Features: High fever, severe headache, retro-orbital pain, myalgia, rash, thrombocytopenia, hemorrhage (tourniquet test positive)
Lab Diagnosis:
  • NS1 antigen (day 1-5) - early marker
  • IgM (from day 5 onwards)
  • IgG (secondary infection)
  • PCR - most sensitive early
Tourniquet Test (Rumpel-Leede): Positive = >20 petechiae per sq inch

⭐ Q10. Agglutination Reactions + Monoclonal Antibodies (Q2)

Agglutination: Clumping of particulate antigens by antibodies.
  • Direct (active): Widal, ABO blood grouping, Cold agglutinins in Mycoplasma
  • Indirect (passive): Latex agglutination (CRP, RF, Cryptococcal Ag)
  • Coombs test: Direct (sensitized RBCs) vs Indirect (for IgG antibodies)
Monoclonal Antibodies (MAbs): Produced by hybridoma technology (B cell + myeloma = hybridoma)
  • Uses: ELISA, Immunofluorescence, Therapeutic (Infliximab, Rituximab, Trastuzumab), Diagnostic (pregnancy tests, tumor markers)

⭐ Q11. Drug Resistance in Bacteria (Q21)

Genetic Mechanisms:
  1. Chromosomal mutation (spontaneous)
  2. R-factor/Plasmid mediated (most common clinically) - via conjugation
  3. Transposons (jumping genes)
  4. Transfer by: Conjugation (main), Transformation, Transduction
Mechanisms of Resistance:
  1. Enzyme inactivation (beta-lactamase destroys penicillin)
  2. Altered target site (MRSA - altered PBP2a)
  3. Efflux pumps
  4. Reduced permeability (porin channel changes)
  5. Bypass pathway
MRSA: Methicillin resistant S. aureus - mecA gene encodes PBP2a (low affinity). Treatment: Vancomycin / Linezolid

⭐ Q12. Entamoeba histolytica (Q12)

Agent: Protozoa. Trophozoite (10-60 µm) and cyst (4 nuclei) forms. Transmission: Feco-oral (contaminated water/food) Pathogenesis: Cyst ingested -> trophozoite in colon -> invasion -> flask-shaped ulcers -> bloody diarrhea. Can spread to liver (amoebic liver abscess)
Lab Diagnosis:
  • Stool exam: Trophozoites with ingested RBCs (pathognomonic)
  • Serology: ELISA (for liver abscess)
  • Aspirate: Anchovy sauce pus (liver abscess), sterile
Amoebic Liver Abscess: Right lobe, "anchovy sauce" aspirate. Sterile - no trophozoites in aspirate usually. Diagnosed by serology + USG Treatment: Metronidazole + Diloxanide furoate (luminal)

⭐ Q13. Diarrheagenic E. coli (Q22)

TypeMechanismDisease
ETECHeat stable (ST) + Heat labile (LT) toxinTraveller's diarrhea
EPECAttaches to mucosa, effacingInfantile diarrhea
EIECInvades mucosaDysentery-like
EHEC (O157:H7)Shiga toxin (verotoxin)HUS, bloody diarrhea
EAECAggregative adherencePersistent diarrhea

⭐ Q14. Leishmaniasis (Q10)

Forms: Kala azar (visceral - L. donovani), Cutaneous (L. tropica), Mucocutaneous (L. braziliensis) Vector: Phlebotomus sandfly (female) Diagnosis of Kala azar:
  • Splenic aspirate - most sensitive (95%)
  • Bone marrow aspirate - safer
  • LD (Leishman-Donovan) bodies in macrophages
  • rK39 antigen test (rapid, field test)
  • Aldehyde (Napier's) test - positive in kala azar
Treatment: Miltefosine (oral, 1st line), Amphotericin B, Sodium stibogluconate

⭐ Q15. Herpes Zoster / Varicella Zoster Virus (Q19, Q38)

Agent: VZV (HHV-3), DNA virus, enveloped Primary infection: Varicella (chickenpox) - centripetal rash (starts on trunk), crops of vesicles Reactivation: Zoster (shingles) - dermatomal distribution, unilateral, painful
Lab Diagnosis: Tzanck smear (multinucleated giant cells), DFA, PCR Treatment: Acyclovir Vaccine: Live attenuated varicella vaccine (Varivax)

⭐ Q16. Cholera (Q37)

Agent: Vibrio cholerae O1/O139, curved Gram -ve rod, darting motility Pathogenesis: CT (Cholera toxin) -> ADP ribosylation of Gs protein -> ↑cAMP -> hypersecretion of Cl-/water -> Rice water diarrhea Lab: TCBS medium (yellow colonies), hanging drop preparation (shooting star motility), string test positive
Treatment: ORS (primary), Doxycycline (drug of choice)

⭐ Q17. Immunoglobulins IgM, IgG, IgA (Q33)

IgG: Most abundant (75%), crosses placenta, secondary immune response, opsonization, ADCC. 4 subclasses.
IgM: First to appear (primary response), pentamer, best agglutinator, classical complement activation, cannot cross placenta. 10 antigen binding sites.
IgA: Secretary immunoglobulin (sIgA), protects mucous membranes (respiratory, GI, GU tracts), dimeric in secretions with J chain + secretory piece. Most produced overall.

Q18. Leprosy (Q40)

Agent: Mycobacterium leprae (cannot be cultured in vitro - grown in armadillo footpad) Types: Tuberculoid (TT) - high CMI, paucibacillary vs Lepromatous (LL) - low CMI, multibacillary
Lab Diagnosis:
  • Slit skin smear: ZN stain, bacteriological index (BI)
  • Lepromin test (Mitsuda reaction): Positive in TT (good immunity), Negative in LL
  • Biopsy of skin/nerve
Treatment (MDT): Paucibacillary - Dapsone + Rifampicin (6 months). Multibacillary - Rifampicin + Dapsone + Clofazimine (12 months)

Q19. Complement Pathways (Q28)

Classical: Ag-Ab complex (IgG/IgM) activates C1q -> C1r -> C1s -> C4 -> C2 -> C3 -> C5-C9 (MAC) Alternative: Directly by microbial surfaces (LPS, fungal wall) -> C3 -> Factor B, D, P (properdin) -> C5-C9 Lectin: MBL binds mannose -> MASP1, MASP2
Common final pathway: C5b -> C6-9 = MAC (Membrane Attack Complex) -> lysis

Q20. Antigen-Antibody Reactions (Q2)

Properties: Specificity, reversibility, non-covalent bonds, equivalence zone Agglutination: Widal (O & H antigens), Blood grouping Precipitation: Ouchterlony (double diffusion), Elek's test (diphtheria toxin) Complement fixation test: (CFT) - older test Neutralization: Virus neutralization

Q21. Giardia lamblia (Q13)

Agent: Flagellate protozoa, pear-shaped trophozoite, "falling leaf" motility, 4 nuclei cyst Transmission: Feco-oral, waterborne Clinical: Malabsorption, steatorrhea, fatty diarrhea (no blood/mucus) Diagnosis: Stool exam (cysts), duodenal aspirate/string test (Enterotest) for trophozoites Treatment: Metronidazole

Q22. Ascaris lumbricoides (Q16)

Largest intestinal nematode. Transmitted by ingesting embryonated eggs. Life cycle: Egg ingested -> larvae hatch -> penetrate intestinal wall -> liver -> heart -> lungs (Loeffler's syndrome) -> trachea -> swallowed -> intestine -> adult worm Complications: Intestinal obstruction, biliary ascariasis, Loeffler's pneumonia Diagnosis: Stool exam (eggs - bile stained, mammillated) Treatment: Albendazole / Mebendazole

Q23. Hookworm - Clinical Case (Q24)

Infective stage: Filariform (L3) larvae (NOT eggs) Mode of infection: Skin penetration (walking barefoot - ground itch) Life cycle: Skin -> blood -> lungs -> trachea -> intestine -> adult worm -> suck blood Complications: Iron deficiency anemia (most common), hypoproteinemia, ground itch, Loeffler's pneumonia Diagnosis: Stool exam (eggs - thin shell, segmented)

Q24. Leptospirosis (Q14)

Agent: Leptospira interrogans (spirochete), zoonosis (reservoir: rats) Transmission: Contact with contaminated water/soil (through skin abrasions) Clinical: Weil's disease = jaundice + renal failure + hemorrhage Lab: Dark field microscopy (blood, 1st week), serology (MAT - Microscopic Agglutination Test), ELISA Treatment: Penicillin / Doxycycline

Q25. Taenia solium (Q15, Paper 2 Q6)

Definitive host: Man (adult tapeworm in intestine - taeniasis) Intermediate host: Pig (cysticercus cellulosae in muscles) Cysticercosis in humans: Man accidentally becomes intermediate host (ingests eggs from contaminated food/water or autoinfection) Neurocysticercosis: Cysticerci in brain -> seizures, raised ICP Diagnosis: Stool (proglottids), CT/MRI brain (neurocysticercosis), serology (ELISA), CT shows "hole with a dot" (scolex in cyst) Treatment: Praziquantel / Albendazole + Steroids (neurocysticercosis)

Q26. Filariasis (Q11)

Agent: Wuchereria bancrofti, Vector: Culex mosquito Life cycle: Infective L3 larvae from mosquito bite -> lymphatics -> adult worm -> microfilariae (nocturnal periodicity) in blood Pathogenesis: Adult worms in lymphatics -> lymphatic obstruction -> lymphedema -> elephantiasis (Lymphedema, hydrocele, chyluria) Diagnosis: Midnight blood smear (Giemsa), Knott's concentration, ICT card test, USG (dancing filaria sign) Treatment: DEC (Diethylcarbamazine), Ivermectin + Albendazole (MDA program)

Q27. Immune Response / CMI (Q23)

Innate Immunity: Non-specific, immediate (skin, mucus, NK cells, complement, phagocytes) Acquired/Adaptive: Specific, memory
  • Active: Natural (infection) or Artificial (vaccination)
  • Passive: Natural (maternal Ab, colostrum) or Artificial (IVIG, antitoxin)
Cell Mediated Immunity (CMI): T lymphocytes (CD4 helper, CD8 cytotoxic)
  • CD4 Th1 -> IL-2, IFN-γ -> macrophage activation -> intracellular pathogens (TB, fungi, viruses)
  • CD8 CTL -> kill virus-infected cells
  • Assessment: Lymphocyte proliferation test, Delayed hypersensitivity skin test (Mantoux)

Q28. MRSA (Q31)

Methicillin Resistant Staphylococcus aureus:
  • mecA gene -> encodes PBP2a (altered penicillin binding protein) -> low affinity for all beta-lactams
  • MRSA resistant to: ALL beta-lactams (penicillins, cephalosporins, carbapenems)
  • Hospital-acquired (HA-MRSA) vs Community-acquired (CA-MRSA)
  • Treatment: Vancomycin (drug of choice), Linezolid, Daptomycin, Tigecycline
  • Detection: Cefoxitin disc diffusion, mecA PCR, VITEK

Q29. Dermatophytes (Q25)

Types: Tinea capitis (scalp), Tinea corporis (ringworm of body), Tinea pedis (athlete's foot), Tinea unguium (nail - onychomycosis), Tinea cruris (jock itch)
Organisms: Trichophyton, Microsporum, Epidermophyton Diagnosis: KOH mount (branching hyphae + arthrospores), Woods lamp (green fluorescence - Microsporum), Culture on Sabouraud's dextrose agar Treatment: Topical antifungals (clotrimazole, miconazole), Terbinafine, Griseofulvin (nails/scalp)

Q30. Gas Gangrene (Q45)

Agent: Clostridium perfringens (type A) - Gram +ve, anaerobic rod, spore-forming Toxin: Alpha toxin (lecithinase/phospholipase C) - most important Features: Wound infection, gas in tissue, sweet smell, crepitus, myonecrosis Diagnosis: Gram stain (Gram +ve rods, no spores in tissue), culture (anaerobic), X-ray (gas in tissue) Treatment: Surgical debridement (MOST important), high dose Penicillin, Hyperbaric O2


PAPER 2 - HIGH YIELD ANSWERS


⭐ Q1. Tuberculosis (Q12)

Agent: Mycobacterium tuberculosis, acid-fast bacillus (ZN stain - red on blue background), slow grower
Pathogenesis: Droplet transmission -> primary complex (Ghon focus + lymphadenopathy) -> healed / progressive primary / post-primary
Lab Diagnosis:
  • Sputum: ZN stain (AFB +ve), Auramine rhodamine fluorescence (sensitive)
  • Culture: LJ medium (6-8 weeks), BACTEC MGIT (2 weeks) - gold standard
  • Molecular: GeneXpert MTB/RIF (detects TB + rifampicin resistance in 2 hrs) - MOST important
  • Line Probe Assay (LPA): MTBDRplus (detects R, H resistance), MTBDRsl (second-line)
  • Tuberculin Skin Test (Mantoux): PPD 5 TU intradermal, read at 48-72 hrs, induration ≥10 mm positive
Treatment (RIPE):
  • Intensive (2 months): Rifampicin + Isoniazid + Pyrazinamide + Ethambutol
  • Continuation (4 months): Rifampicin + Isoniazid
  • MDR-TB: Resistant to R + H. XDR-TB: MDR + Fluoroquinolone + injectable resistance
Atypical Mycobacteria (NTM): M. avium complex (MAC), M. kansasii, M. fortuitum, M. marinum ("fish tank granuloma"), M. ulcerans (Buruli ulcer)

⭐ Q2. Bacterial Meningitis (Q8)

Common organisms by age:
  • Neonates: Group B Streptococcus, E. coli, Listeria
  • Children: Neisseria meningitidis, H. influenzae
  • Adults: Neisseria meningitidis, S. pneumoniae
  • Elderly: S. pneumoniae, Listeria
Lab Diagnosis of Meningitis - CSF Analysis:
ParameterNormalBacterialViralTBFungal
AppearanceClearTurbidClearFibrin webClear
Cells0-5>1000 (PMN)<500 (Lymph)100-500 (Lymph)Lymph
Protein20-45↑↑Normal/↑↑↑
Glucose50-80%↓↓Normal
Meningococcal Meningitis: N. meningitidis, Gram -ve diplococci (kidney bean shaped), causes Waterhouse-Friderichsen syndrome (bilateral adrenal hemorrhage)
Cryptococcal Meningitis: C. neoformans, India ink prep (capsule visible as halo), latex agglutination (capsular polysaccharide), mainly in HIV patients. Treatment: Amphotericin B + Flucytosine, then Fluconazole
TB Meningitis: CSF - cobweb clot, lymphocytes, high protein, low glucose, AFB (rarely positive), ADA elevated

⭐ Q3. Syphilis (Q11)

Agent: Treponema pallidum (spirochete), not culturable in vitro Transmission: Sexual contact, vertical (congenital), blood
Stages:
  • Primary: Painless chancre (single, indurated, clean base) at site of inoculation
  • Secondary: Condylomata lata, maculopapular rash (palms & soles), highly infectious
  • Latent: No symptoms, serology positive
  • Tertiary: Gumma (any organ), cardiovascular (aortitis), neurosyphilis
Lab Diagnosis:
  • Direct: Dark field microscopy (primary/secondary lesions), DFA
  • Non-treponemal (screening): VDRL, RPR (quantitative, disease activity)
  • Treponemal (confirmatory): TPHA, FTA-ABS, TPPA (remain positive for life)
RPR Test: Cardiolipin antigen + charcoal particles. Flocculation test. Quantitative. Biological false positive: SLE, pregnancy, malaria, infections
Treatment: Benzathine Penicillin G (drug of choice for all stages)

⭐ Q4. Rabies (Q3)

Agent: Lyssavirus (Rhabdovirus), ss RNA, bullet-shaped Transmission: Bite of infected animal (dog most common) Pathogenesis: Virus enters peripheral nerve -> travels to CNS (centripetal) -> replicates -> spreads to salivary glands Pathognomonic: Negri bodies (eosinophilic cytoplasmic inclusions in Purkinje cells of cerebellum, hippocampus)
Lab Diagnosis:
  • Post-mortem: Negri bodies (H&E or Sellers stain), FAT (most sensitive)
  • Antemortem: Skin biopsy (nape of neck), CSF, Saliva - DFA/PCR
PEP (Post Exposure Prophylaxis):
  1. Wound washing (soap + water 15 min - most important)
  2. RIG (Rabies Immunoglobulin): HRIG 20 IU/kg - infiltrate wound + IM (if not vaccinated previously)
  3. Vaccine: 4 doses (days 0, 3, 7, 14) - Purified chick embryo cell (PCEC) / PVRV

⭐ Q5. Streptococcus pyogenes (Q7)

Group A Streptococcus (GAS), beta-hemolytic
Virulence factors: M protein (anti-phagocytic, main virulence), Streptolysin S & O, Streptokinase, Hyaluronidase, Erythrogenic toxin (scarlet fever)
Diseases: Pharyngitis, Impetigo, Scarlet fever, Erysipelas, Necrotizing fasciitis, Toxic shock-like syndrome
Post-streptococcal complications:
  • Rheumatic fever (pharyngitis, not skin) - carditis, arthritis, Sydenham's chorea, subcutaneous nodules, erythema marginatum
  • Post-streptococcal glomerulonephritis (PSGN) - pharyngitis or skin infection
Lab: Culture on blood agar (beta hemolysis), Bacitracin sensitive (differentiates from other streptococci), ASO titer (retrospective diagnosis)

⭐ Q6. Diphtheria (Q2)

Agent: Corynebacterium diphtheriae, Gram +ve rod, Chinese letter arrangement, club shaped (metachromatic/Babes-Ernst granules) Toxin: Exotoxin (coded by beta phage) - inhibits protein synthesis by ADP-ribosylation of EF-2 (elongation factor 2) Disease: Pseudomembrane in throat (grayish-white, bleeds on removal), Bull neck, myocarditis, neuropathy
Lab: Loeffler's serum slope (metachromatic granules), Tellurite agar (black/gray colonies), Elek's gel precipitation test (toxigenicity)
Schick Test: Intradermal diphtheria toxin. Positive = susceptible (no antitoxin). Negative = immune. Treatment: Diphtheria antitoxin (DAT) + Penicillin/Erythromycin

⭐ Q7. Polio Virus (Q4)

Agent: Picornavirus, Enterovirus, 3 serotypes (P1, P2, P3) Transmission: Feco-oral Pathogenesis: Oropharynx -> GI tract -> viremia -> anterior horn cells of spinal cord -> flaccid paralysis (lower motor neuron) Vaccine Comparison:
FeatureOPV (Sabin)IPV (Salk)
TypeLive attenuatedKilled
RouteOralInjection
ImmunityMucosal (IgA) + HumoralHumoral only
Herd immunityYesNo
RiskVAPP (1:2.4 million)None
StorageCold chain requiredMore stable

⭐ Q8. Influenza / Swine Flu (Q5)

Agent: Orthomyxovirus, ss RNA, segmented (8 segments) Antigens: Hemagglutinin (HA) - attachment, Neuraminidase (NA) - release Antigenic Shift: Major change (reassortment of segments) -> pandemic Antigenic Drift: Minor change (point mutations) -> seasonal epidemics
H1N1 (Swine Flu):
  • Diagnosis: RT-PCR (nasopharyngeal swab) - gold standard
  • Treatment: Oseltamivir (Tamiflu), Zanamivir
  • Prophylaxis: Annual influenza vaccine (trivalent/quadrivalent)

⭐ Q9. Clostridium tetani (Q14)

Agent: Gram +ve, anaerobic spore-forming rod. Drumstick appearance (terminal spore). Toxin: Tetanospasmin (neurotoxin) - blocks release of inhibitory neurotransmitters (GABA, Glycine) at Renshaw cells -> spastic paralysis Features: Trismus (lockjaw), risus sardonicus, opisthotonos Lab: Clinical diagnosis. Culture difficult. Treatment: Tetanus antitoxin (HTIG), Penicillin, Metronidazole, muscle relaxants, wound debridement Prevention: Tetanus toxoid (TT) vaccine - 3 doses (DTP/Td schedule). Booster every 10 years.

⭐ Q10. Gonorrhea & STIs (Q1, Paper 2)

Agent: Neisseria gonorrhoeae, Gram -ve diplococci (intracellular in PMNs - pathognomonic) Other STI organisms: Treponema pallidum (syphilis), Chlamydia trachomatis (NGU, LGV), HSV-2, HPV, Trichomonas vaginalis, Haemophilus ducreyi (chancroid)
Pathogenesis: Pili + OMP -> attachment to columnar epithelium -> inflammation -> purulent discharge Complications: PID, Fitz-Hugh-Curtis syndrome (perihepatitis), DGI, ophthalmia neonatorum (in newborn) Lab: Gram stain (urethral discharge) - diplococci in PMNs, Culture on Thayer-Martin medium (modified chocolate agar + antibiotics), NAAT (most sensitive) Treatment: Ceftriaxone + Azithromycin (dual therapy)

⭐ Q11. Echinococcus granulosus (Q9)

Agent: Dog tapeworm, causes Hydatid disease/cystic echinococcosis Definitive host: Dog/wolf. Intermediate host: Sheep, cattle, humans (accidentally) Transmission: Ingesting eggs from dog feces Site: Liver (most common), Lung Structure: Hydatid cyst - pericyst (host), ectocyst (laminated membrane), endocyst (germinal layer), brood capsules, scolices, hydatid sand
Diagnosis: USG (best), CT scan, Casoni test (intradermal), serology (ELISA), Eosinophilia Treatment: PAIR (Puncture, Aspiration, Injection of hypertonic saline/ethanol, Re-aspiration) + Albendazole. Surgery. Caution: Do NOT aspirate blindly - risk of anaphylaxis from spillage

Q12. Plague (Q13)

Agent: Yersinia pestis, Gram -ve bipolar staining ("safety pin" appearance), zoonosis (rats) Vector: Rat flea (Xenopsylla cheopis)
Clinical Types:
  1. Bubonic plague: Bubo (painful lymph node enlargement in groin/axilla)
  2. Pneumonic plague: Most dangerous, person-to-person, 100% mortality if untreated
  3. Septicemic plague: DIC, hemorrhage
Lab: Wayson stain (bipolar safety pin), Culture, Fluorescent antibody test Treatment: Streptomycin (drug of choice), Doxycycline, Ciprofloxacin

Q13. Aspergillosis (Q23)

Agent: Aspergillus fumigatus (most common), A. flavus, A. niger Morphology: Septate hyphae with acute angle branching (45°), fruiting bodies
Forms:
  • Allergic Bronchopulmonary Aspergillosis (ABPA): Asthma + eosinophilia + fleeting shadows
  • Aspergilloma: Fungal ball in pre-existing cavity (Monod sign/air crescent sign on X-ray)
  • Invasive Aspergillosis: Immunocompromised (neutropenia) - most serious
  • Otomycosis: External ear infection
Diagnosis: Culture (SDA), Galactomannan (serum/BAL), Beta-glucan, CT chest (halo sign in invasive), Biopsy Treatment: Voriconazole (drug of choice), Amphotericin B

Q14. Mycobacterium tuberculosis - Molecular Methods (Q12)

  • GeneXpert MTB/RIF: Cartridge-based PCR, detects TB + rifampicin resistance in 2 hours
  • Line Probe Assay (LPA): GenoType MTBDRplus (detects rpoB, inhA, katG mutations = R+H resistance)
  • MALDI-TOF: Rapid identification
  • CBNAAT: Same as Xpert (Cartridge Based NAAT)
  • LAMP (Loop-mediated isothermal amplification): Field use

Q15. COVID-19 (Q15)

Agent: SARS-CoV-2, Betacoronavirus, enveloped, +ss RNA, large genome Spike protein (S): Binds ACE2 receptor on type II pneumocytes Pathogenesis: ACE2 entry -> viral replication -> cytokine storm -> ARDS, hypercoagulability, multiorgan failure Lab: RT-PCR (gold standard), Rapid Antigen Test (screening), Antibody (past infection/vaccine response) Treatment: Remdesivir, Dexamethasone (for severe/hypoxemic), Nirmatrelvir-ritonavir (Paxlovid)

Q16. Neisseria Meningitidis (Q8)

Gram -ve diplococci, ferments glucose AND maltose (differentiates from N. gonorrhoeae) Capsular polysaccharide groups: A, B, C, W135, Y Waterhouse-Friderichsen syndrome: Bilateral adrenal hemorrhage, purpuric rash, shock (meningococcemia) Lab: CSF - Gram stain (diplococci), culture on chocolate agar/Thayer-Martin, meningococcal antigen detection Treatment: Penicillin G / Ceftriaxone Prophylaxis: Rifampicin (contacts), Meningococcal vaccine (ACWY)

Q17. Chlamydia / LGV (Q20)

C. trachomatis - obligate intracellular pathogen
  • Serotypes A, B, Ba: Trachoma (blindness)
  • Serotypes D-K: NGU, PID, neonatal conjunctivitis
  • Serotypes L1, L2, L3: Lymphogranuloma venereum (LGV)
LGV: Painless papule/ulcer -> painful inguinal lymphadenopathy (bubo) -> groove sign (buboes above and below inguinal ligament) Diagnosis: Serology (complement fixation), NAAT Treatment: Doxycycline (21 days)

Q18. Toxoplasma gondii (Q32)

Definitive host: Cat (sexual cycle). Intermediate host: All warm-blooded animals/humans Transmission: Ingestion of oocysts (cat feces) or tissue cysts (undercooked meat), vertical Congenital Toxoplasmosis: Tetrad: Hydrocephalus, chorioretinitis, intracranial calcifications, psychomotor retardation Diagnosis: Serology (ELISA - IgM acute), PCR (amniotic fluid), CT (ring-enhancing lesions in HIV) Treatment: Pyrimethamine + Sulfadiazine + Folinic acid

Q19. Mycoplasma Pneumonia / Atypical Pneumonia (Q35)

Agent: Mycoplasma pneumoniae - smallest free-living organism, NO cell wall Features: "Walking pneumonia" - mild, insidious onset. Doesn't respond to beta-lactams (no cell wall target). Lab: Cold agglutinins (IgM against I antigen on RBCs), serology (ELISA), Culture on Eaton's medium (requires cholesterol) Diagnosis: Serology (complement fixation, ELISA), PCR Treatment: Macrolides (Azithromycin), Doxycycline, Fluoroquinolones

Q20. Brucellosis (Q45)

Agent: Brucella (Gram -ve coccobacilli), zoonosis. B. abortus (cattle), B. melitensis (goats - most virulent), B. suis (pigs) Transmission: Ingestion of unpasteurized milk/cheese, direct contact with animals Lab Diagnosis:
  • Blood culture (Castaneda's medium - most definitive)
  • Serology: SAT (Standard Agglutination Test) titer ≥1:160 significant, Rose Bengal test (screening), ELISA
  • Brucellergy test (skin test) Treatment: Doxycycline + Rifampicin (6 weeks) - combination essential

Q21. Trichomonas vaginalis (Q33)

Agent: Flagellate protozoa, ONLY trophozoite form (no cyst), pear-shaped, 4 anterior flagella + undulating membrane Clinical: Vaginal discharge (frothy, greenish-yellow, foul smelling), strawberry cervix, dysuria Lab: Wet mount (saline) - pear-shaped motile trophozoites, culture (Diamond's medium), NAAT Treatment: Metronidazole (single dose 2g) - treat both partners

Q22. Pertussis (Q50)

Agent: Bordetella pertussis, Gram -ve coccobacillus Toxin: Pertussis toxin (ADP-ribosylation of Gi protein) -> lymphocytosis, ↑histamine sensitization Stages: Catarrhal (most contagious) -> Paroxysmal (whooping cough - whoop during inspiration) -> Convalescent Lab: Pernasal swab/NPA -> Bordet-Gengou medium (potato blood agar), PCR Treatment: Azithromycin (or Erythromycin), Amoxicillin Vaccine: DTP/DTaP vaccine

Q23. Naegleria fowleri (Q29)

Primary Amoebic Meningoencephalitis (PAM) Transmission: Swimming in warm freshwater lakes/ponds (enters via cribriform plate) Trophozoite forms: Amoeboid, Flagellate (distinguishing feature), Cyst Clinical: Fulminant meningoencephalitis, almost always fatal Diagnosis: CSF - motile trophozoites, CT brain, culture Treatment: Amphotericin B (rarely successful), Miltefosine

Q24. Slow Viral Infections (Q24)

DiseaseAgentFeature
KuruPrionCannibalism (Fore tribe), cerebellar ataxia
CJD (Creutzfeldt-Jakob)PrionRapidly progressive dementia, myoclonus
SSPEMeasles virusSubacute sclerosing panencephalitis, progressive dementia
PMLJC virusIn immunocompromised
HIV encephalopathyHIV
Prions: Proteinaceous infectious particles. PrPc (normal) -> PrPsc (misfolded, disease-causing). No nucleic acid. Resistant to heat, UV, formalin.

Q25. Oncogenic Viruses (Q36)

VirusAssociated Cancer
HPV 16, 18Cervical, oropharyngeal carcinoma
EBVBurkitt lymphoma, NPC, Hodgkin's
HBV, HCVHepatocellular carcinoma
HTLV-1Adult T-cell leukemia/lymphoma
HHV-8 (KSHV)Kaposi sarcoma
MCPyVMerkel cell carcinoma

Q26. Japanese Encephalitis (Q40)

Agent: Flavivirus (RNA), Vector: Culex tritaeniorhynchus mosquito, Reservoir: Pigs + Wading birds Clinical: Encephalitis, fever, seizures, Parkinsonian features Lab: IgM capture ELISA (CSF/serum), RT-PCR, CSF - lymphocytic pleocytosis Treatment: Supportive Vaccine: SA14-14-2 live attenuated (most used), Inactivated JE vaccine (IXIARO)

Q27. Viral Hemorrhagic Fevers (Q38)

Includes: Ebola, Marburg, Lassa, Crimean-Congo HF, Dengue HF, Yellow fever, Hantavirus Common features: Fever, hemorrhage, thrombocytopenia, high mortality Ebola: Filovirus, fruit bats (reservoir), human-to-human contact, treatment: Zmapp (monoclonal Ab) Dengue HF: Platelet <100,000, hematocrit ↑>20%, hemorrhagic manifestations Crimean-Congo HF: Tick-borne (Hyalomma tick), Ribavirin treatment Lassa fever: Rodent reservoir, Ribavirin treatment

Q28. Mumps (Q49)

Agent: Paramyxovirus, ss RNA, enveloped, spiky surface Features: Parotitis (painful bilateral), Orchitis (post-pubertal males - can cause infertility), Meningitis, Pancreatitis Lab: Serology (ELISA IgM), viral culture (urine/saliva), RT-PCR Treatment: Supportive Vaccine: MMR (live attenuated)

Q29. Congenital Rubella Syndrome (Q47)

Gregg's triad: Cataracts + Congenital heart defects (PDA, pulmonary stenosis) + Sensorineural deafness Risk highest: First trimester (>80% risk) Other features: Blueberry muffin rash (extramedullary hematopoiesis), microcephaly, IUGR Lab: IgM (baby), virus isolation from urine, PCR Prevention: MMR vaccine (pre-conception), avoid in pregnancy

Q30. Zygomycosis / Mucormycosis (Q46)

Agents: Rhizopus, Mucor, Absidia (class Zygomycetes/Mucorales) Morphology: Broad, non-septate hyphae, wide-angle (90°) branching - distinguishes from Aspergillus Predisposing: Diabetes (DKA - most common), immunosuppression, iron chelation therapy (deferoxamine) Forms: Rhinocerebral (most common), Pulmonary, Cutaneous, GI, Disseminated Lab: KOH mount/Biopsy (wide non-septate hyphae), culture on SDA, iron stain (iron-loving) Treatment: Liposomal Amphotericin B + aggressive surgical debridement

AETCOM KEY POINTS (Both Papers)

For ALL sensitive results (HIV, HBV, HCV) disclosure:
  1. Call patient in private setting (not over phone)
  2. Maintain confidentiality
  3. Use simple non-technical language
  4. Show empathy, do not be judgmental
  5. Explain disease, treatment options, prognosis
  6. Counseling - partner notification, safe sex, blood donation restriction
  7. Follow local NACO/hospital guidelines
Informed Consent (surgery communication):
  1. Nature of disease + diagnosis
  2. Nature of surgery + alternatives
  3. Risks and benefits
  4. Right to refuse
  5. Post-operative care
  6. Use vernacular language if needed
5 Moments of Hand Hygiene (WHO):
  1. Before patient contact
  2. Before aseptic procedure
  3. After body fluid exposure
  4. After patient contact
  5. After contact with patient surroundings

Study Priority Order: Paper 1: HIV > Malaria > Typhoid > Hepatitis > Hypersensitivity > Sterilization > Drug resistance > ELISA > Cholera > E. histolytica Paper 2: TB > Meningitis > Syphilis > Rabies > Gonorrhea > Diphtheria > Polio > Tetanus > Influenza > EchinococcusThat's your complete cheat sheet! Here's a quick summary of what's covered:
Paper 1 - 30 topics answered including all ⭐ high-yield ones: HIV/AIDS, Typhoid, Hypersensitivity (all 4 types), Autoimmunity/SLE, Malaria (including cerebral malaria), Hepatitis viruses (all markers), Sterilization/Autoclave, ELISA, Dengue, Drug resistance/MRSA, E. histolytica/Liver abscess, Diarrheagenic E. coli, Leishmaniasis, VZV/Herpes zoster, Cholera, Immunoglobulins, Leprosy, Complement pathways, Giardia, Ascaris, Hookworm, Leptospirosis, Taenia solium, Filariasis, CMI/Immunity types, Dermatophytes, Gas gangrene + more
Paper 2 - 30 topics answered including all ⭐ high-yield ones: TB (all molecular methods), Bacterial/TB/Cryptococcal Meningitis, Syphilis/RPR, Rabies/PEP, Strep pyogenes, Diphtheria/Elek's test, Polio (OPV vs IPV), Influenza/H1N1, Tetanus, Gonorrhea/STIs, Echinococcus, Plague, Aspergillosis, COVID-19, Chlamydia/LGV, Toxoplasma, Atypical pneumonia, Brucellosis, Trichomonas, Pertussis, Naegleria, Slow viruses/Prions, Oncogenic viruses, JE, VHFs, Mumps, Congenital Rubella, Zygomycosis + AETCOM
Topics NOT yet covered (less likely but can do if time permits): Actinomycosis, Campylobacter, Blood culture methods, Enrichment/selective media, Allograft/GVHD, Larva migrans, Toxic shock syndrome, Viral gastroenteritis, Enterobius, H. pylori, Satellite phenomenon, Anaerobic vaginosis, Tularemia, Borrelia vincenti, Paragonimiasis - let me know if you want any of these!

Send the text Again

NTRUHS 2K23 MICROBIOLOGY - CHEAT SHEET


PAPER 1 - HIGH YIELD ANSWERS


⭐ Q1. HIV/AIDS (Q7)

Structure: Enveloped, ss-RNA retrovirus. Icosahedral core.
  • Structural genes: gag (p24 core), pol (RT, integrase, protease), env (gp120, gp41)
  • Non-structural genes: tat, rev, nef, vif, vpr, vpu
Pathogenesis: HIV binds CD4 + CCR5/CXCR4 -> enters T-helper cell -> RT makes proviral DNA -> integrates -> replication -> CD4 count falls -> AIDS (<200 cells/µL)
Lab Diagnosis:
  • ELISA (screening) -> Western Blot (confirmation)
  • CD4 count, Viral load (PCR)
  • NACO algorithm: 3 rapid tests (A1, A2, A3)
ART: TDF + 3TC + EFV (first line) PEP: Start within 72 hrs, give for 28 days
Opportunistic fungal infections: Candidiasis (most common), Cryptococcal meningitis, PCP (Pneumocystis jirovecii), Histoplasmosis, Aspergillosis

⭐ Q2. Typhoid Fever (Q6)

Agent: Salmonella typhi (Gram -ve rod) Pathogenesis: Feco-oral -> Peyer's patches -> bacteremia -> rose spots, hepatosplenomegaly
Widal Test:
  • Positive: O titer ≥1:80, H titer ≥1:160 (single); O ≥1:160 (paired)
  • O = active infection, H = past infection/vaccination
Lab Diagnosis: Gold standard = Blood culture (1st week), Urine/stool culture (3rd week), Bone marrow culture (most sensitive)
Treatment: Ciprofloxacin / Azithromycin / Ceftriaxone Vaccine: Vi polysaccharide (injectable), Ty21a (oral live attenuated) Drug Resistance: MDR typhoid - resistant to Amp, Chloramphenicol, Co-trimoxazole. XDR - also resistant to fluoroquinolones

⭐ Q3. Hypersensitivity Reactions (Q4)

TypeNameMediatorExample
IAnaphylactic/ImmediateIgE, Mast cellsAnaphylaxis, Asthma, Urticaria
IICytotoxicIgG/IgM + ComplementABO incompatibility, Autoimmune hemolytic anemia
IIIImmune ComplexIgG complexes + ComplementSLE, Serum sickness, Post-strep GN
IVDelayed (Cell mediated)T lymphocytesTB (Mantoux), Contact dermatitis, Graft rejection
Shwartzman Reaction: Two injections of endotoxin (preparatory + provocative) -> local (skin) or generalized (DIC, bilateral cortical necrosis)

⭐ Q4. Autoimmunity + SLE (Q1)

Mechanisms of Autoimmunity:
  1. Molecular mimicry (pathogen resembles self Ag)
  2. Polyclonal B cell activation
  3. Sequestered antigen release
  4. Defective Treg function
  5. Bystander activation
SLE:
  • ANA - screening test
  • Anti-dsDNA - specific, correlates with disease activity
  • Anti-Smith (Anti-Sm) - most specific
  • Features: Butterfly rash, arthritis, nephritis, serositis, hematologic changes
  • LE cells seen in peripheral smear
Classification: Organ-specific (Hashimoto's, Type 1 DM, MG) vs Systemic (SLE, RA, Sjogren's)

⭐ Q5. Malaria (Q9)

Plasmodium species: P. falciparum (malignant tertian, most dangerous), P. vivax (benign tertian), P. malariae (quartan), P. ovale
Life Cycle:
  • Mosquito (Anopheles female): Sexual cycle (sporogony) -> Sporozoites
  • Human: Liver (exo-erythrocytic) -> RBC (erythrocytic) -> Trophozoite -> Schizont -> Merozoites
Pathogenesis: Rupture of RBCs -> fever, chills. P. falciparum - cytoadherence, rosetting -> cerebral malaria
Lab Diagnosis:
  • Peripheral smear (Giemsa stain) - Gold standard
  • RDT - HRP2 antigen for P. falciparum
  • PCR
Cerebral Malaria: P. falciparum only. Parasitized RBCs block cerebral capillaries. Features: Coma, seizures, mortality ~20%
Treatment: Chloroquine (sensitive), ACT - Artemether+Lumefantrine (falciparum), Primaquine (for P. vivax hypnozoites)
Vaccine: RTS,S (Mosquirix) - first approved malaria vaccine

⭐ Q6. Hepatitis Viruses (Q17)

VirusTypeTransmissionChronicityMarkers
HAVRNAFeco-oralNoAnti-HAV IgM (acute)
HBVDNABlood/sexual/verticalYes (5-10%)HBsAg, HBeAg, Anti-HBc IgM
HCVRNABloodYes (80%)Anti-HCV, PCR
HDVRNA (incomplete)Blood (needs HBV)YesAnti-HDV
HEVRNAFeco-oralNoAnti-HEV IgM
HBV Markers:
  • HBsAg: First to appear, marker of infection
  • HBeAg: Active replication, high infectivity
  • Anti-HBs: Immunity (natural or vaccine)
  • Anti-HBc IgM: Acute infection
  • Window period: HBsAg gone, Anti-HBs not yet - only Anti-HBc IgM present
Prophylaxis HBV: Vaccine (3 doses: 0, 1, 6 months) + HBIG for post-exposure

⭐ Q7. Sterilization & Disinfection (Q5)

Sterilization: Complete destruction of ALL microorganisms including spores.
Moist Heat (most reliable):
  • Autoclave: 121°C, 15 psi, 15 min (kills spores)
  • Pasteurization: 62°C/30 min (LTLT) or 72°C/15 sec (HTST)
  • Boiling: 100°C, 20 min (NOT sterilization - doesn't kill spores)
Dry Heat:
  • Hot air oven: 160°C/60 min, 170°C/30 min, 180°C/10 min
High Level Disinfectants: Glutaraldehyde 2% (Cidex), Hydrogen peroxide 6%, Formaldehyde, OPA (Ortho-phthalaldehyde)
Gaseous Disinfectants: Ethylene oxide (ETO) - heat-sensitive items; Formaldehyde vapor
Chemical Disinfectants: Phenol (carbolic acid, first antiseptic), Alcohol 70%, Chlorine compounds (hypochlorite), Povidone-iodine

⭐ Q8. ELISA (Q3)

Principle: Antigen-antibody reaction detected by enzyme-linked antibody producing color change.
Types:
  1. Direct ELISA - detect antigen
  2. Indirect ELISA - detect antibody (most common in serology)
  3. Sandwich ELISA - most sensitive, detect antigen
  4. Competitive ELISA
Enzymes used: HRP (Horseradish peroxidase), Alkaline phosphatase
Uses: HIV screening, HBsAg, Dengue NS1, TORCH screening

⭐ Q9. Dengue (Q8)

Agent: Flavivirus, ss RNA, 4 serotypes (DEN 1-4), Aedes aegypti mosquito
Pathogenesis: Secondary infection with different serotype -> Antibody-Dependent Enhancement (ADE) -> more severe disease (DHF/DSS)
Clinical Features: High fever, retro-orbital pain, myalgia, rash, thrombocytopenia, hemorrhage
Lab Diagnosis:
  • NS1 antigen (day 1-5) - early marker
  • IgM (from day 5 onwards)
  • IgG (secondary infection marker)
  • PCR - most sensitive early
Tourniquet Test (Rumpel-Leede): Positive = >20 petechiae per sq inch

⭐ Q10. Agglutination Reactions + Monoclonal Antibodies (Q2)

Agglutination: Clumping of particulate antigens by antibodies.
  • Direct: Widal, ABO blood grouping, Cold agglutinins (Mycoplasma)
  • Indirect (passive): Latex agglutination (CRP, RF, Cryptococcal Ag)
  • Coombs test: Direct (sensitized RBCs) vs Indirect (detect IgG antibodies in serum)
Monoclonal Antibodies: Produced by hybridoma technology (B cell + myeloma cell = hybridoma)
  • Uses: Diagnostic (pregnancy tests, tumor markers) and Therapeutic (Infliximab, Rituximab, Trastuzumab)

⭐ Q11. Drug Resistance in Bacteria (Q21)

Genetic Mechanisms:
  1. Chromosomal mutation (spontaneous)
  2. Plasmid/R-factor mediated (most common clinically)
  3. Transposons (jumping genes)
  4. Transfer by: Conjugation (main route), Transformation, Transduction
Mechanisms of Resistance:
  1. Enzyme inactivation - beta-lactamase destroys penicillin
  2. Altered target site - MRSA (altered PBP2a)
  3. Efflux pumps
  4. Reduced permeability (porin channel changes)
  5. Bypass pathway
MRSA: mecA gene encodes PBP2a (low affinity for all beta-lactams). Treatment: Vancomycin / Linezolid

⭐ Q12. Entamoeba histolytica (Q12)

Agent: Trophozoite (10-60 µm, ingested RBCs - pathognomonic) and cyst (4 nuclei) Transmission: Feco-oral
Pathogenesis: Cyst ingested -> trophozoite in colon -> flask-shaped ulcers -> bloody diarrhea -> may spread to liver
Lab Diagnosis:
  • Stool: Trophozoites with ingested RBCs
  • Serology: ELISA (liver abscess)
Amoebic Liver Abscess: Right lobe, "anchovy sauce" aspirate, sterile. Diagnosed by serology + USG.
Treatment: Metronidazole + Diloxanide furoate (luminal cyst killer)

⭐ Q13. Diarrheagenic E. coli (Q22)

TypeMechanismDisease
ETECLT + ST toxinTraveller's diarrhea
EPECAttaches, effacingInfantile diarrhea
EIECInvades mucosaDysentery-like
EHEC (O157:H7)Shiga toxin (Verotoxin)HUS, bloody diarrhea
EAECAggregative adherencePersistent diarrhea

⭐ Q14. Leishmaniasis (Q10)

Forms: Kala azar (visceral - L. donovani), Cutaneous (L. tropica), Mucocutaneous (L. braziliensis) Vector: Phlebotomus sandfly (female)
Diagnosis of Kala azar:
  • Splenic aspirate - most sensitive (95%)
  • Bone marrow aspirate - safer alternative
  • LD bodies in macrophages
  • rK39 antigen rapid test
  • Aldehyde (Napier's) test - positive in kala azar
Treatment: Miltefosine (oral, 1st line), Amphotericin B, Sodium stibogluconate

⭐ Q15. Herpes Zoster / VZV (Q19, Q38)

Agent: VZV (HHV-3), DNA virus, enveloped Primary infection: Varicella (chickenpox) - centripetal rash, crops of vesicles at different stages Reactivation: Zoster (shingles) - dermatomal, unilateral, painful
Lab: Tzanck smear (multinucleated giant cells), DFA, PCR Treatment: Acyclovir Vaccine: Live attenuated varicella vaccine

⭐ Q16. Cholera (Q37)

Agent: Vibrio cholerae O1/O139, curved Gram -ve rod, darting motility
Pathogenesis: CT (Cholera toxin) -> ADP ribosylation of Gs protein -> ↑cAMP -> hypersecretion Cl-/water -> Rice water diarrhea
Lab: TCBS medium (yellow colonies), hanging drop (shooting star motility), string test positive
Treatment: ORS (primary), Doxycycline (drug of choice)

⭐ Q17. Immunoglobulins - IgM, IgG, IgA (Q33)

IgG: Most abundant (75%), crosses placenta, secondary immune response, opsonization, ADCC. 4 subclasses.
IgM: First to appear (primary response), pentamer (10 binding sites), best agglutinator, classical complement activation, CANNOT cross placenta.
IgA: Secretary immunoglobulin (sIgA), protects mucous membranes (respiratory, GI, GU). Dimeric in secretions with J chain + secretory piece. Most produced overall.

Q18. Leprosy (Q40)

Agent: M. leprae - cannot be cultured in vitro, grown in armadillo footpad
FeatureTuberculoid (TT)Lepromatous (LL)
CMIHighLow
BacilliPaucibacillaryMultibacillary
Lepromin testPositiveNegative
LesionsFew, well-definedMultiple, diffuse
Lab: Slit skin smear (ZN stain), Lepromin test (Mitsuda reaction), biopsy
Treatment (MDT):
  • Paucibacillary: Dapsone + Rifampicin (6 months)
  • Multibacillary: Rifampicin + Dapsone + Clofazimine (12 months)

Q19. Complement Pathways (Q28)

Classical: Ag-Ab complex (IgG/IgM) -> C1q -> C1r -> C1s -> C4 -> C2 -> C3 -> C5-C9 (MAC)
Alternative: Microbial surfaces (LPS, fungal wall) directly -> C3 -> Factor B, D, Properdin -> C5-C9
Lectin: MBL binds mannose -> MASP1, MASP2 -> C4, C2
Common final pathway: C5b -> C6-C9 = MAC (Membrane Attack Complex) -> cell lysis

Q20. Giardia lamblia (Q13)

Agent: Flagellate protozoa, pear-shaped trophozoite, "falling leaf" motility, 4 nuclei cyst Transmission: Feco-oral, waterborne
Clinical: Malabsorption, steatorrhea, fatty diarrhea (NO blood/mucus)
Diagnosis: Stool (cysts), duodenal aspirate/Enterotest (string test) for trophozoites
Treatment: Metronidazole

Q21. Ascaris lumbricoides (Q16)

Largest intestinal nematode. Transmission: ingesting embryonated eggs.
Life cycle: Egg -> larvae -> intestine -> liver -> heart -> lungs (Loeffler's pneumonia) -> trachea -> swallowed -> intestine -> adult
Complications: Intestinal obstruction, biliary ascariasis, Loeffler's syndrome
Diagnosis: Stool exam (bile-stained mammillated eggs)
Treatment: Albendazole / Mebendazole

Q22. Hookworm - Clinical Case (Q24)

Infective stage: Filariform (L3) larvae - NOT eggs
Mode of infection: Skin penetration (barefoot - ground itch)
Life cycle: Skin -> blood -> lungs -> trachea -> intestine -> blood-sucking adult worms
Complications: Iron deficiency anemia (severe - Hb 5g/dl), hypoproteinemia, Loeffler's pneumonia
Diagnosis: Stool exam (thin-shelled, segmented eggs)

Q23. Leptospirosis (Q14)

Agent: Leptospira interrogans (spirochete), zoonosis (reservoir: rats) Transmission: Contact with water/soil contaminated with animal urine (through skin abrasions)
Weil's disease: Jaundice + renal failure + hemorrhage (severe form)
Lab: Dark field microscopy (blood, week 1), MAT (Microscopic Agglutination Test - gold standard serology), ELISA
Treatment: Penicillin / Doxycycline

Q24. Taenia solium (Q15)

Definitive host: Man (adult tapeworm - taeniasis) Intermediate host: Pig (cysticercus cellulosae in muscles) Cysticercosis in humans: Man accidentally becomes intermediate host (ingests eggs)
Neurocysticercosis: Cysticerci in brain -> seizures, raised ICP. CT: "hole with a dot" (scolex in cyst)
Diagnosis: Stool (proglottids), CT/MRI brain, serology (ELISA)
Treatment: Praziquantel / Albendazole + Steroids (neurocysticercosis)

Q25. Filariasis (Q11)

Agent: Wuchereria bancrofti, Vector: Culex mosquito (night biting)
Life cycle: L3 larvae from bite -> lymphatics -> adult worm -> microfilariae (nocturnal periodicity) in blood
Pathogenesis: Adult worms in lymphatics -> obstruction -> elephantiasis, hydrocele, chyluria
Diagnosis: Midnight blood smear (Giemsa), Knott's concentration, ICT card test, USG (dancing filaria sign)
Treatment: DEC, Ivermectin + Albendazole (MDA program)

Q26. CMI / Immune Response (Q23)

Innate: Non-specific, immediate (skin, mucus, NK cells, complement, phagocytes)
Acquired:
  • Active Natural: infection; Active Artificial: vaccination
  • Passive Natural: maternal Ab/colostrum; Passive Artificial: IVIG, antitoxin
CMI:
  • CD4 Th1 -> IL-2, IFN-γ -> macrophage activation -> intracellular pathogens (TB, fungi, viruses)
  • CD8 CTL -> kill virus-infected cells
Assessment of CMI: Lymphocyte proliferation test, Delayed hypersensitivity skin test (Mantoux)

Q27. MRSA (Q31)

  • mecA gene -> encodes PBP2a -> low affinity for ALL beta-lactams
  • Resistant to: ALL penicillins, cephalosporins, carbapenems
  • HA-MRSA (hospital) vs CA-MRSA (community)
  • Treatment: Vancomycin (DOC), Linezolid, Daptomycin
  • Detection: Cefoxitin disc diffusion, mecA PCR

Q28. Dermatophytes (Q25)

Organisms: Trichophyton, Microsporum, Epidermophyton
Types: Tinea capitis (scalp), Tinea corporis (body), Tinea pedis (athlete's foot), Tinea unguium (nail), Tinea cruris (groin)
Diagnosis: KOH mount (branching hyphae + arthrospores), Wood's lamp (green fluorescence - Microsporum), Culture on SDA
Treatment: Topical antifungals (clotrimazole), Terbinafine, Griseofulvin (nails/scalp)

Q29. Gas Gangrene (Q45)

Agent: Clostridium perfringens type A, Gram +ve anaerobic rod, spore-forming Alpha toxin (lecithinase/phospholipase C): Main virulence factor
Features: Gas in tissue, sweet smell, crepitus, myonecrosis, wound infection
Diagnosis: Gram stain (Gram +ve rods), X-ray (gas in tissue), anaerobic culture
Treatment: Surgical debridement (MOST important) + high dose Penicillin + Hyperbaric O2


PAPER 2 - HIGH YIELD ANSWERS


⭐ Q1. Tuberculosis (Q12)

Agent: M. tuberculosis, acid-fast bacillus (ZN stain - red on blue), slow grower
Pathogenesis: Droplet transmission -> primary complex (Ghon focus + hilar lymphadenopathy) -> healed / progressive / post-primary TB
Lab Diagnosis:
  • ZN stain: AFB red on blue background
  • Auramine rhodamine fluorescence: more sensitive
  • Culture: LJ medium (6-8 weeks), BACTEC MGIT (2 weeks) - gold standard
  • GeneXpert MTB/RIF: Detects TB + Rifampicin resistance in 2 hours - MOST IMPORTANT
  • Line Probe Assay (LPA): MTBDRplus detects rpoB (R), inhA/katG (H) mutations
  • Tuberculin Skin Test (Mantoux): PPD 5TU intradermal, read at 48-72 hrs, ≥10 mm = positive
Treatment (RIPE):
  • Intensive phase (2 months): Rifampicin + Isoniazid + Pyrazinamide + Ethambutol
  • Continuation phase (4 months): Rifampicin + Isoniazid
  • MDR-TB: Resistant to R + H. XDR-TB: MDR + Fluoroquinolone + injectable drug resistance
Atypical Mycobacteria (NTM): MAC, M. kansasii, M. fortuitum, M. marinum ("fish tank granuloma"), M. ulcerans (Buruli ulcer)

⭐ Q2. Bacterial Meningitis (Q8)

Organisms by age:
  • Neonates: Group B Strep, E. coli, Listeria
  • Children: N. meningitidis, H. influenzae
  • Adults: N. meningitidis, S. pneumoniae
  • Elderly: S. pneumoniae, Listeria
CSF Analysis:
ParameterBacterialViralTBFungal
AppearanceTurbidClearFibrin webClear
Cells>1000 PMN<500 Lymph100-500 LymphLymph
Protein↑↑Normal/↑↑↑
Glucose↓↓Normal
Meningococcal Meningitis: N. meningitidis, Gram -ve diplococci. Waterhouse-Friderichsen syndrome (bilateral adrenal hemorrhage, purpuric rash, shock)
Cryptococcal Meningitis: C. neoformans, India ink (capsule as halo), latex agglutination, mainly in HIV. Treatment: Amphotericin B + Flucytosine -> Fluconazole
TB Meningitis: Cobweb clot CSF, lymphocytes, high protein, low glucose, ADA elevated

⭐ Q3. Syphilis (Q11)

Agent: Treponema pallidum (spirochete), not culturable
Stages:
  • Primary: Painless chancre (single, indurated, clean base)
  • Secondary: Condylomata lata, maculopapular rash on palms & soles, highly infectious
  • Latent: Serology positive, no symptoms
  • Tertiary: Gumma, cardiovascular syphilis (aortitis), neurosyphilis
Lab Diagnosis:
  • Direct: Dark field microscopy (primary/secondary lesions)
  • Non-treponemal (screening + quantitative): VDRL, RPR
  • Treponemal (confirmatory): TPHA, FTA-ABS, TPPA (remain positive for life)
RPR Test: Cardiolipin antigen + charcoal particles. Flocculation test. Biological false positive: SLE, pregnancy, malaria
Treatment: Benzathine Penicillin G (DOC for all stages)

⭐ Q4. Rabies (Q3)

Agent: Lyssavirus (Rhabdovirus), ss RNA, bullet-shaped Transmission: Bite of infected animal (dog most common)
Pathogenesis: Virus enters peripheral nerve -> travels centripetally to CNS -> replicates -> spreads to salivary glands
Pathognomonic: Negri bodies (eosinophilic cytoplasmic inclusions in Purkinje cells of cerebellum / hippocampus)
Lab Diagnosis:
  • Post-mortem: Negri bodies (Sellers stain), FAT (most sensitive)
  • Antemortem: Skin biopsy (nape of neck), saliva, CSF - DFA/PCR
Post Exposure Prophylaxis (PEP):
  1. Wound washing with soap + water for 15 min (MOST important step)
  2. RIG (HRIG 20 IU/kg) - infiltrate wound if not previously vaccinated
  3. Vaccine: 4 doses on days 0, 3, 7, 14 (PCEC or PVRV)

⭐ Q5. Streptococcus pyogenes (Q7)

Group A Strep (GAS), beta-hemolytic
Virulence factors: M protein (main, anti-phagocytic), Streptolysin S & O (SLO), Streptokinase, Hyaluronidase, Erythrogenic toxin (scarlet fever)
Diseases: Pharyngitis, Impetigo, Scarlet fever, Erysipelas, Necrotizing fasciitis
Post-streptococcal complications:
  • Rheumatic fever (after pharyngitis only): Carditis, arthritis, Sydenham's chorea, erythema marginatum, subcutaneous nodules
  • PSGN (after pharyngitis or skin infection): Hematuria, hypertension, edema
Lab: Blood agar (beta hemolysis), Bacitracin sensitive, ASO titer (retrospective)

⭐ Q6. Diphtheria (Q2)

Agent: Corynebacterium diphtheriae, Gram +ve rod, Chinese letter arrangement, metachromatic granules (Babes-Ernst)
Toxin: Exotoxin (coded by beta phage) - ADP-ribosylation of EF-2 (elongation factor 2) -> inhibits protein synthesis -> myocarditis, neuropathy
Disease: Grayish-white pseudomembrane (bleeds on removal), bull neck, myocarditis, palatal palsy
Lab:
  • Loeffler's serum slope (metachromatic granules)
  • Tellurite agar (black/gray colonies)
  • Elek's gel precipitation test (toxigenicity)
Schick Test: Positive = susceptible (no antitoxin). Negative = immune.
Treatment: Diphtheria antitoxin (DAT) + Penicillin/Erythromycin

⭐ Q7. Polio Virus (Q4)

Agent: Picornavirus/Enterovirus, 3 serotypes (P1, P2, P3), feco-oral transmission
Pathogenesis: Oropharynx -> GI -> viremia -> anterior horn cells -> flaccid paralysis (LMN)
OPV vs IPV:
FeatureOPV (Sabin)IPV (Salk)
TypeLive attenuatedKilled
RouteOralInjection
ImmunityMucosal IgA + HumoralHumoral only
Herd immunityYesNo
RiskVAPP (1:2.4 million)None

⭐ Q8. Influenza / Swine Flu (Q5)

Agent: Orthomyxovirus, ss RNA, 8 segments Key antigens: HA (hemagglutinin - attachment), NA (neuraminidase - release)
Antigenic Shift: Major change - reassortment -> Pandemic Antigenic Drift: Minor change - point mutations -> Seasonal epidemics
H1N1:
  • Diagnosis: RT-PCR (nasopharyngeal swab)
  • Treatment: Oseltamivir (Tamiflu), Zanamivir
  • Prevention: Annual influenza vaccine

⭐ Q9. Clostridium tetani (Q14)

Agent: Gram +ve anaerobe, spore-forming. Drumstick appearance (terminal spore).
Tetanospasmin: Blocks GABA and Glycine at Renshaw cells -> loss of inhibition -> spastic paralysis
Features: Trismus (lockjaw), risus sardonicus, opisthotonos
Treatment: HTIG (Human Tetanus Immunoglobulin) + Penicillin/Metronidazole + Diazepam + wound debridement
Prevention: TT vaccine (DTP schedule). Booster every 10 years.

⭐ Q10. Gonorrhea & STIs (Paper 2, Q1)

Agent: Neisseria gonorrhoeae, Gram -ve diplococci (intracellular in PMNs - pathognomonic)
Other STI organisms: T. pallidum (syphilis), C. trachomatis (NGU/LGV), HSV-2, HPV, T. vaginalis, H. ducreyi (chancroid)
Complications: PID, Fitz-Hugh-Curtis syndrome (perihepatitis), ophthalmia neonatorum, DGI
Lab: Gram stain (intracellular diplococci), Culture on Thayer-Martin medium, NAAT (most sensitive)
Treatment: Ceftriaxone + Azithromycin (dual therapy)

⭐ Q11. Echinococcus granulosus (Q9)

Definitive host: Dog. Intermediate host: Sheep, cattle, humans (accidental) Transmission: Ingesting eggs from dog feces Site: Liver (most common), then Lung
Hydatid cyst structure: Pericyst (host) + ectocyst (laminated) + endocyst (germinal) + brood capsules + scolices + hydatid sand
Diagnosis: USG (best), CT, Casoni test (intradermal), serology (ELISA), eosinophilia
Treatment: PAIR (Puncture, Aspiration, Injection hypertonic saline, Re-aspiration) + Albendazole. Surgery if needed. NEVER blindly aspirate - risk of anaphylaxis.

Q12. Plague (Q13)

Agent: Yersinia pestis, Gram -ve bipolar "safety pin" staining (Wayson stain), zoonosis (rats) Vector: Rat flea (Xenopsylla cheopis)
Clinical Types:
  1. Bubonic: Bubo (painful lymphadenopathy in groin/axilla)
  2. Pneumonic: Most dangerous, person-to-person transmission, ~100% fatal untreated
  3. Septicemic: DIC, hemorrhage
Treatment: Streptomycin (DOC), Doxycycline, Ciprofloxacin

Q13. Aspergillosis (Q23)

Agent: Aspergillus fumigatus (most common). Septate hyphae with 45° (acute angle) branching.
Forms:
  • ABPA: Asthma + eosinophilia + fleeting shadows on X-ray
  • Aspergilloma: Fungal ball in pre-existing cavity (Monod sign / air crescent sign)
  • Invasive Aspergillosis: Immunocompromised (neutropenic) - most serious. CT: halo sign
  • Otomycosis: External ear
Diagnosis: Culture (SDA), Galactomannan antigen, Beta-glucan, CT chest, biopsy
Treatment: Voriconazole (DOC), Amphotericin B

Q14. COVID-19 (Q15)

Agent: SARS-CoV-2, Betacoronavirus, +ss RNA, enveloped
Pathogenesis: Spike protein binds ACE2 on type II pneumocytes -> viral replication -> cytokine storm -> ARDS, hypercoagulability, multiorgan failure
Lab: RT-PCR (gold standard), Rapid Antigen Test (screening), Antibody (past infection/vaccine)
Treatment: Remdesivir, Dexamethasone (severe/hypoxemic), Nirmatrelvir-ritonavir (Paxlovid)

Q15. Chlamydia / LGV (Q20)

C. trachomatis - obligate intracellular, no cell wall
  • Serotypes A, B, Ba: Trachoma (leading cause of preventable blindness)
  • Serotypes D-K: NGU, PID, neonatal conjunctivitis
  • Serotypes L1, L2, L3: LGV
LGV stages: Painless papule -> painful inguinal bubo -> groove sign (lymphadenopathy above + below inguinal ligament)
Diagnosis: NAAT, serology (CFT) Treatment: Doxycycline 100 mg BD x 21 days

Q16. Toxoplasma gondii (Q32)

Definitive host: Cat (sexual cycle). Intermediate host: All warm-blooded animals + humans
Transmission: Oocysts (cat feces), tissue cysts (undercooked meat), transplacental
Congenital Toxoplasmosis Tetrad:
  1. Hydrocephalus
  2. Chorioretinitis
  3. Intracranial calcifications
  4. Psychomotor retardation
In HIV: Ring-enhancing lesions on CT brain
Diagnosis: Serology (IgM = acute), PCR (amniotic fluid), CT brain Treatment: Pyrimethamine + Sulfadiazine + Folinic acid

Q17. Atypical Pneumonia / Mycoplasma (Q35)

Agent: Mycoplasma pneumoniae - smallest free-living organism, NO cell wall -> NOT sensitive to beta-lactams
Features: "Walking pneumonia" - mild, insidious, community-acquired in young adults
Lab:
  • Cold agglutinins (IgM against RBC I antigen) - non-specific
  • Culture on Eaton's medium (requires cholesterol)
  • Serology (CFT, ELISA), PCR
Treatment: Macrolides (Azithromycin), Doxycycline, Fluoroquinolones

Q18. Brucellosis (Q45)

Agent: Brucella - Gram -ve coccobacilli, zoonosis
  • B. abortus (cattle), B. melitensis (goats - most virulent), B. suis (pigs)
Transmission: Unpasteurized milk/cheese, direct contact with infected animals
Lab Diagnosis:
  • Blood culture: Castaneda's medium (most definitive)
  • Serology: SAT titer ≥1:160 significant, Rose Bengal test (screening), ELISA
Treatment: Doxycycline + Rifampicin (6 weeks) - combination is essential to prevent relapse

Q19. Trichomonas vaginalis (Q33)

Agent: Flagellate protozoa, ONLY trophozoite form (no cyst), pear-shaped, 4 anterior flagella
Clinical: Frothy greenish-yellow foul-smelling vaginal discharge, strawberry cervix, dysuria
Lab: Wet mount (saline) - pear-shaped motile trophozoites, culture (Diamond's medium), NAAT
Treatment: Metronidazole 2g single dose - treat BOTH partners

Q20. Pertussis / Whooping Cough (Q50)

Agent: Bordetella pertussis, Gram -ve coccobacillus
Pertussis toxin: ADP-ribosylation of Gi protein -> lymphocytosis
Stages:
  1. Catarrhal (most contagious): cold-like symptoms
  2. Paroxysmal: Whooping cough (whoop on inspiration), post-tussive vomiting
  3. Convalescent: gradual recovery
Lab: Pernasal swab/NPA -> Bordet-Gengou medium (potato blood agar), PCR
Treatment: Azithromycin (or Erythromycin) Vaccine: DTP/DTaP

Q21. Naegleria fowleri (Q29)

Primary Amoebic Meningoencephalitis (PAM)
Transmission: Swimming in warm freshwater (enters via cribriform plate)
Unique feature: Exists in 3 forms: Amoeboid, Flagellate (distinguishing), Cyst
Clinical: Fulminant meningoencephalitis, almost 100% fatal
Diagnosis: CSF - motile trophozoites, culture, CT brain
Treatment: Amphotericin B (rarely successful), Miltefosine (newer option)

Q22. Slow Viral Infections / Prions (Q24, Q42)

DiseaseAgentFeature
KuruPrionCannibalism (Fore tribe), cerebellar ataxia
CJDPrionRapidly progressive dementia, myoclonus
SSPEMeasles virusProgressive dementia in children after measles
PMLJC virusImmunocompromised patients
Prions: PrPc (normal) -> PrPsc (misfolded, disease-causing). No nucleic acid. Resistant to heat, UV, formalin.

Q23. Oncogenic Viruses (Q36)

VirusAssociated Cancer
HPV 16, 18Cervical carcinoma, oropharyngeal
EBVBurkitt lymphoma, NPC, Hodgkin's
HBV + HCVHepatocellular carcinoma
HTLV-1Adult T-cell leukemia/lymphoma
HHV-8 (KSHV)Kaposi sarcoma
MCPyVMerkel cell carcinoma

Q24. Japanese Encephalitis (Q40)

Agent: Flavivirus (RNA). Vector: Culex tritaeniorhynchus. Reservoir: Pigs + Wading birds
Clinical: Encephalitis, seizures, Parkinsonian features, mask-like facies
Lab: IgM capture ELISA (CSF/serum), RT-PCR, CSF - lymphocytic pleocytosis
Vaccine: SA14-14-2 (live attenuated), IXIARO (inactivated)

Q25. Viral Hemorrhagic Fevers (Q38)

VHFAgentVector/ReservoirTreatment
EbolaFilovirusFruit bats, contactZmapp (MAb)
LassaArenavirusRodentsRibavirin
CCHFBunyavirusHyalomma tickRibavirin
Yellow feverFlavivirusAedes mosquitoSupportive
Dengue HFFlavivirusAedes aegyptiSupportive

Q26. Mumps (Q49)

Agent: Paramyxovirus, ss RNA Features: Bilateral parotitis (painful), Orchitis (post-pubertal males - infertility risk), Meningitis, Pancreatitis
Lab: Serology (IgM ELISA), RT-PCR Treatment: Supportive Vaccine: MMR (live attenuated)

Q27. Congenital Rubella Syndrome (Q47)

Gregg's Triad:
  1. Cataracts
  2. Congenital heart defects (PDA, pulmonary stenosis)
  3. Sensorineural deafness
Risk: Highest in first trimester (>80%)
Other features: Blueberry muffin rash, microcephaly, IUGR
Diagnosis: IgM in baby, virus isolation from urine, PCR
Prevention: MMR vaccine pre-conception. CONTRAINDICATED in pregnancy.

Q28. Zygomycosis / Mucormycosis (Q46)

Agents: Rhizopus (most common), Mucor, Absidia
Morphology: Broad, NON-septate hyphae with wide angle (90°) branching - distinguishes from Aspergillus (which is septate, 45°)
Predisposing factors: Diabetes (DKA - most common), neutropenia, deferoxamine therapy
Forms: Rhinocerebral (most common), Pulmonary, Cutaneous
Diagnosis: KOH mount/biopsy (wide non-septate hyphae), culture on SDA
Treatment: Liposomal Amphotericin B + aggressive surgical debridement


AETCOM KEY POINTS (Both Papers)

Disclosing sensitive results (HIV/HBV/HCV):
  1. Private setting, face-to-face (never over phone)
  2. Maintain strict confidentiality
  3. Simple, non-technical language
  4. Show empathy, non-judgmental attitude
  5. Explain disease, treatment, prognosis
  6. Counseling: partner notification, safe sex, avoid blood donation
  7. Follow NACO/hospital guidelines
Informed Consent (surgery):
  1. Nature of diagnosis
  2. Nature of surgery + alternatives
  3. Risks and benefits
  4. Right to refuse
  5. Post-operative care
  6. Use vernacular language if needed
5 Moments of Hand Hygiene (WHO):
  1. Before patient contact
  2. Before aseptic procedure
  3. After body fluid exposure
  4. After patient contact
  5. After contact with patient surroundings

Study Priority: Paper 1: HIV > Malaria > Typhoid > Hepatitis > Hypersensitivity > Sterilization > Drug resistance > ELISA > Cholera > E. histolytica
Paper 2: TB > Meningitis > Syphilis > Rabies > Gonorrhea > Diphtheria > Polio > Tetanus > Influenza > Echinococcus

Can you name these questions under their respective chapter names only question is enough no need giving whole answer again

Here are all questions from both papers organized under their chapter names:

PAPER 1


Immunology

  • Autoimmunity, Mechanisms, SLE, Autoimmune diseases classification
  • Antigen-Antibody Reactions, Agglutination, Monoclonal Antibodies
  • ELISA
  • Hypersensitivity Reactions (Type I, II, III, IV), Shwartzman Reaction
  • Define Immune Response, Cell Mediated Immunity, Active/Passive/Innate/Acquired Immunity
  • Alternative & Classical Complement Pathways
  • Structure and Functions of IgM, IgA, IgG
  • Allograft Reaction, Graft Versus Host Disease

General Microbiology

  • Sterilization, Moist Heat, Autoclave, Disinfectants (High level, Gaseous, Chemical)
  • Enrichment Media, Selective Media
  • Anaerobic Culture Methods
  • Mechanism of Drug Resistance, Genetic Mechanisms, Antimicrobial Resistance
  • MRSA (Methicillin Resistant Staphylococcus Aureus)
  • Blood Culture Methods for Infective Endocarditis
  • Moments of Hand Hygiene
  • Standard / Universal Precautions
  • Louis Pasteur, Robert Koch

Bacteriology

  • Enteric (Typhoid) Fever, Widal Test, Drug Resistance, Vaccine
  • Diarrheagenic E. coli
  • Cholera
  • Leptospirosis
  • Bacillary Dysentery (Pathogenesis + Lab Diagnosis)
  • Gas Gangrene
  • Helicobacter Pylori
  • Campylobacter Infections
  • Leprosy, Laboratory Diagnosis
  • Actinomycosis, Mycetoma
  • Toxic Shock Syndrome
  • Mechanisms of Bacterial Pathogenesis
  • Food poisoning case (Bacillus cereus - Chinese fried rice scenario)

Virology

  • HIV/AIDS, Western Blot, NACO, ART, PEP, Opportunistic Fungal Infections
  • Dengue, Pathogenesis, Clinical, Investigations, Treatment
  • Hepatitis Viruses, Morphology, Serological Markers, Prophylaxis of HBV, Hepatitis C
  • Herpes Zoster
  • Varicella Zoster Virus
  • Viral Gastroenteritis
  • Lab Diagnosis of Viral Infections

Parasitology

  • Malaria, Life Cycle, Pathogenesis, Lab Diagnosis, Vaccine, Cerebral Malaria
  • Leishmaniasis, Life Cycle, Lab Diagnosis, Treatment
  • Bancroftian Filariasis, Lymphatic Filariasis
  • Entamoeba histolytica
  • Giardia lamblia
  • Taenia Solium
  • Ascaris lumbricoides
  • Hookworm (clinical case - pallor, Hb 5g/dl)
  • Larva Migrans
  • Enterobius Vermicularis
  • Amoebic Liver Abscess
  • Cysticercus Cellulosae

Mycology

  • Dermatophytes / Dermatophytoses
  • Lab Diagnosis of Fungal Infections


PAPER 2


Bacteriology

  • Neisseria Gonorrhoeae, STI organisms, Pathogenesis, Diagnosis, Management
  • Diphtheria
  • Streptococcus Pyogenes
  • Bacterial Meningitis, Lab Diagnosis, Meningococcal Meningitis, Tuberculous Meningitis
  • Tuberculosis, Molecular Methods, Pathogenesis, Treatment, Tuberculin Skin Test, Atypical Mycobacteria
  • Plague, Clinical Types
  • Clostridium Tetani, Tetanus Prevention
  • Complications of Post-Streptococcal Infection
  • Satellitism
  • Anaerobic Vaginosis
  • Bacillus anthracis, Cutaneous Anthrax, Pulmonary Anthrax
  • Urinary Tract Infections, Lab Diagnosis
  • Acute Pyelonephritis - Causative Organisms + Pathogenesis
  • Yersinia pestis
  • Chancroid
  • Lymphogranuloma Venereum
  • Non-Gonococcal Urethritis
  • Borrelia Vincenti
  • Brucellosis, Lab Diagnosis
  • Tularemia
  • Pertussis (Whooping Cough)
  • Elek's Gel Precipitation Test
  • Atypical Pneumonia (Mycoplasma Pneumonia)
  • Infection Control Policy

Virology

  • Rabies, PEP, Morphology, Pathogenesis, Lab Diagnosis
  • Picornavirus (Polio), OPV vs IPV
  • Myxovirus, Influenza, Swine Flu, H1N1 Diagnosis & Prophylaxis
  • Covid-19, Pathogenesis
  • Slow Viral Infections
  • Oncogenic Viruses
  • Viral Hemorrhagic Fevers
  • Japanese B Encephalitis
  • Congenital Rubella Syndrome
  • Mumps
  • Prions
  • Rapid Plasma Reagin (RPR) Test

Parasitology

  • Taenia Solium
  • Classify Cestodes, Echinococcus granulosus - Life Cycle, Pathogenesis, Lab Diagnosis
  • Cerebral Malaria
  • Neurocysticercosis
  • Naegleria fowleri
  • Primary Amoebic Encephalitis
  • Morphology and Life Cycle of Toxoplasma gondii
  • Trichomonas vaginalis
  • Paragonimiasis

Mycology

  • Pneumocystis Pneumonia (PCP)
  • Aspergillosis
  • Histoplasmosis
  • Zygomycosis, Opportunistic Mycoses

STIs / Genitourinary

  • Classify STDs, Syphilis, Pathogenesis, Lab Diagnosis, Primary & Secondary Syphilis
  • Lymphogranuloma Venereum
  • Chancroid
  • Non-Gonococcal Urethritis
  • Anaerobic Vaginosis
  • Trichomonas vaginalis

Note: A few topics appear in both papers (Taenia solium, Cerebral malaria) - study them once thoroughly and you're covered for both!

Why some chapters were in both paper I and 2

Great question! Here's why:

NTRUHS Paper 1 vs Paper 2 - How They're Divided

NTRUHS (and most Indian medical universities) split Microbiology into two separate exam papers based on broad subject divisions, not strictly by chapter. Here's the typical logic:

Paper 1 focuses on:

  • General Microbiology (sterilization, culture media, lab methods)
  • Immunology (hypersensitivity, vaccines, antibodies)
  • Parasitology (most of it)
  • Some Bacteriology (GI pathogens mostly - Salmonella, Vibrio, E. coli)
  • Some Virology (HIV, Dengue, Hepatitis)

Paper 2 focuses on:

  • Systemic Bacteriology (organ-system based - respiratory, STIs, CNS, urinary)
  • Mycology (fungi)
  • More Virology (Rabies, Polio, Influenza, Slow viruses)
  • STIs as a group

Why Overlap Happens

  1. Parasitology is huge - Taenia solium, Cerebral malaria naturally spill into both papers depending on the examiner's focus (general parasite in P1, CNS complication in P2)
  2. Examiners set questions independently for each paper - there's no strict "this topic only in P1" rule
  3. Topics like Meningitis are partly bacteriology (P2) and partly lab diagnosis/immunology (P1)
  4. These are "Super-50" prep sheets - compiled by coaching institutes covering ALL likely questions across both papers, so some topics are listed in both intentionally to make sure you don't miss them

Bottom line: Don't worry about which paper a topic "belongs to" - just study the topic once and you're prepared for either paper!
This is a shared conversation. Sign in to Orris to start your own chat.